Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice
A wide range of biological agents recently introduced into clinical rheumatology determines a special interest in their tolerance. The paper presents the authors’ own data, as well as a review of foreign literature on this issue.Objective: to analyze the tolerability of infliximab (INF) in patients...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2020-02-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2840 |
| _version_ | 1797862667839340544 |
|---|---|
| author | E. S. Aronova G. V. Lukina Ya. A. Sigidin |
| author_facet | E. S. Aronova G. V. Lukina Ya. A. Sigidin |
| author_sort | E. S. Aronova |
| collection | DOAJ |
| description | A wide range of biological agents recently introduced into clinical rheumatology determines a special interest in their tolerance. The paper presents the authors’ own data, as well as a review of foreign literature on this issue.Objective: to analyze the tolerability of infliximab (INF) in patients with rheumatoid arthritis (RA) in real clinical practiceSubjects and methods. The analysis included 135 RA patients receiving INF alone or in combination with diseasemodifying antirheumatic drugs.Results and discussion. The total tolerance of INF was satisfactory. Adverse reactions (ARs) were noted in 28.1% of cases, including in 19 (14.1%) patients who had serious ARs that required drug discontinuation.Conclusion. The best tolerance was observed with a combination of INF and methotrexate. The authors draw attention to the need for medical examination prior to each drug administration. |
| first_indexed | 2024-04-09T22:23:16Z |
| format | Article |
| id | doaj.art-aef04e6f076645559a8a473e208046b3 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:23:16Z |
| publishDate | 2020-02-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-aef04e6f076645559a8a473e208046b32023-03-22T13:45:55ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922020-02-01581313610.14412/1995-4484-2020-31-362574Infliximab tolerance in patients with rheumatoid arthritis in real clinical practiceE. S. Aronova0G. V. Lukina1Ya. A. Sigidin2V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare DepartmentV.A. Nasonova Research Institute of RheumatologyA wide range of biological agents recently introduced into clinical rheumatology determines a special interest in their tolerance. The paper presents the authors’ own data, as well as a review of foreign literature on this issue.Objective: to analyze the tolerability of infliximab (INF) in patients with rheumatoid arthritis (RA) in real clinical practiceSubjects and methods. The analysis included 135 RA patients receiving INF alone or in combination with diseasemodifying antirheumatic drugs.Results and discussion. The total tolerance of INF was satisfactory. Adverse reactions (ARs) were noted in 28.1% of cases, including in 19 (14.1%) patients who had serious ARs that required drug discontinuation.Conclusion. The best tolerance was observed with a combination of INF and methotrexate. The authors draw attention to the need for medical examination prior to each drug administration.https://rsp.mediar-press.net/rsp/article/view/2840biological therapybiological agentsinfliximabtumor necrosis factor-а inhibitorsadverse reactionsrheumatoid arthritis |
| spellingShingle | E. S. Aronova G. V. Lukina Ya. A. Sigidin Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice Научно-практическая ревматология biological therapy biological agents infliximab tumor necrosis factor-а inhibitors adverse reactions rheumatoid arthritis |
| title | Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice |
| title_full | Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice |
| title_fullStr | Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice |
| title_full_unstemmed | Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice |
| title_short | Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice |
| title_sort | infliximab tolerance in patients with rheumatoid arthritis in real clinical practice |
| topic | biological therapy biological agents infliximab tumor necrosis factor-а inhibitors adverse reactions rheumatoid arthritis |
| url | https://rsp.mediar-press.net/rsp/article/view/2840 |
| work_keys_str_mv | AT esaronova infliximabtoleranceinpatientswithrheumatoidarthritisinrealclinicalpractice AT gvlukina infliximabtoleranceinpatientswithrheumatoidarthritisinrealclinicalpractice AT yaasigidin infliximabtoleranceinpatientswithrheumatoidarthritisinrealclinicalpractice |